EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drugtamer‐PROTAC Conjugation Strategy for Targeted PROTAC Delivery and Synergistic Antitumor Therapy

Shipeng He, Yuxin Fang, Yaojin Zhu, Ziyang Ma, Guoqiang Dong, Chunquan Sheng iD

Advanced Science · 2024

DOI: 10.1002/advs.202401623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Shipeng He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, Shanghai University, 99 Shangda Road, Shanghai, 200444, P. R. China. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis‐targeting chimeras (PROTACs) have emerged as a promising strategy for targeted protein degradation and drug discovery. To overcome the inherent limitations of conventional PROTACs, an innovative drugtamer‐PROTAC conjugation approach is developed to enhance tumor targeting and antitumor potency. Specifically, a smart prodrug is designed by conjugating “drugtamer” to a nicotinamide phosphoribosyltransferase (NAMPT) PROTAC using a tumor microenvironment responsible linker. The “drugtamer” consists of fluorouridine nucleotide and DNA‐like oligomer. Compared to NAMPT PROTAC and the combination of PROTAC + fluorouracil, the designed prodrug AS‐2F‐NP demonstrates superior tumor targeting, efficient cellular uptake, improved in vivo potency and reduced side effects. This study provides a promising strategy for the precise delivery of PROTAC and synergistic antitumor agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsAnimalsMiceHumansCell Line, TumorProteolysisDrug Delivery SystemsProdrugsDisease Models, AnimalNicotinamide PhosphoribosyltransferaseTumor MicroenvironmentDrug Synergism

Stichwörter der Autor:innen

NAMPTPROTACdrug combinationdrugtamerfluorouracil

Substanzen

Antineoplastic AgentsProdrugsNicotinamide Phosphoribosyltransferase

Autor:innen und Institutionen

  • Institute of Translational Medicine, Shanghai University, 99 Shangda Road, Shanghai, 200444, P. R. China.
  • Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Second Military Medical University (Naval Medical University), 325 Guohe Road, Shanghai, 200433, P. R. China.

ORCID-Profile: Chunquan Sheng

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

He, S., Fang, Y., Zhu, Y., Ma, Z., Dong, G., & Sheng, C. (2024). Drugtamer‐PROTAC Conjugation Strategy for Targeted PROTAC Delivery and Synergistic Antitumor Therapy. Advanced Science. https://doi.org/10.1002/advs.202401623

Vancouver

He S, Fang Y, Zhu Y, Ma Z, Dong G, Sheng C. Drugtamer‐PROTAC Conjugation Strategy for Targeted PROTAC Delivery and Synergistic Antitumor Therapy. Advanced Science. 2024. doi:10.1002/advs.202401623

BibTeX
@article{He2024,
  author = {He, Shipeng and Fang, Yuxin and Zhu, Yaojin and Ma, Ziyang and Dong, Guoqiang and Sheng, Chunquan},
  title = {Drugtamer‐PROTAC Conjugation Strategy for Targeted PROTAC Delivery and Synergistic Antitumor Therapy},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202401623}
}
Kostenlos starten →